XML 27 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2
Vitaros Licensing and Distribution Agreements (Tables)
 9 Months Ended
Sep. 30, 2016
Disclosure - Licensing and Research and Development Agreements [Abstract]  
License Revenue and Expected Future License Revenue
The following table summarizes the total revenue by commercialization partner recorded in the Company’s consolidated statements of operations (in thousands):
 
 
Three Months Ended 
 September 30,
 
Nine Months Ended 
 September 30,
 
 
2016 (1)
 
2015
 
2016 (1)
 
2015
Ferring International Center S.A. ("Ferring")
 
$
3,850

 
$
—

 
$
3,850

 
$
—

Laboratories Majorelle ("Majorelle")
 
157

 
84

 
490

 
84

Bracco SpA (“Bracco”)
 
11

 
—

 
137

 
—

Sandoz (2)
 
—

 
1,109

 
16

 
1,725

Recordati Ireland Ltd. ("Recordati")
 
28

 
42

 
114

 
120

Takeda Pharmaceuticals International GmbH (“Takeda”) (3)
 
—

 
38

 
214

 
281

Elis Pharmaceuticals Limited ("Elis")
 
100

 
—

 
100

 
—

 
 
$
4,146

 
$
1,273

 
$
4,921

 
$
2,210

(1) Product sales to the Company’s contract manufacturers are not shown in the table above since they were unrelated to any of the Company’s commercialization partners. License revenue from parties unrelated to Vitaros® are also not shown above.
(2) Effective July 2016, the Company terminated its license agreement with Sandoz, transitioning the commercialization of Vitaros® in Sandoz’s prior territory to Ferring International Center S.A.
(3) Effective April 2016, the Company terminated its license agreement with Takeda, transitioning the commercialization of Vitaros® in Takeda’s prior territory to Ferring International Center S.A.

The following table summarizes the potential future milestones the Company was eligible for by commercialization partner (in thousands) as of September 30, 2016:
Commercialization Partner
 
Regulatory Milestones (1)
 
Commercial Launch Milestones (1)
 
Sales Milestones (1)
 
Total
Ferring International Center S.A. ("Ferring")
 
$
2,000

 
$
1,500

 
$
24,500

 
$
28,000

Majorelle
 
2,000

 
—

 
17,394

 
19,394

Bracco
 
—

 
—

 
5,050

 
5,050

Recordati
 
—

 
1,122

 
38,715

 
39,837

Abbott Laboratories Limited, now a subsidiary of Mylan N.V. (“Mylan”)
 
225

 
—

 
13,000

 
13,225

Allergan
 
—

 
25,000

 
—

 
25,000

Elis Pharmaceuticals Limited (“Elis”)
 
—

 
—

 
1,900

 
1,900

Neopharm Scientific Limited (“Neopharm”)
 
250

 
—

 
4,000

 
4,250

 
 
$
4,475

 
$
27,622

 
$
104,559

 
$
136,656

(1) Certain contractual amounts have been converted to USD based on the applicable exchange rate as of September 30, 2016.